Rheumatoid Arthritis Clinical Trial Landscape
Data updated: May 20, 2026
1,067 clinical trials tracked since 2008
Rheumatoid Arthritis (RA) is a chronic autoimmune disease primarily affecting the joints, causing inflammation and pain. It impacts a significant portion of the global population, leading to disability and reduced quality of life. The clinical trial landscape for RA reflects ongoing efforts to develop new and improved treatments, with 1,066 trials registered since 2008. Currently, 144 trials are actively recruiting, enrolling, or active but not recruiting patients. A substantial portion of these active trials are in Phase 1 (53 trials) and Phase 2 (50 trials), suggesting a strong focus on early-stage drug development and proof-of-concept studies. Phase 3 trials account for 21 active trials, while Phase 4 trials account for 30. Among industry sponsors, Eli Lilly, AstraZeneca, Bristol-Myers Squibb, AbbVie, and Novartis are the most active, each sponsoring multiple ongoing trials. The high number of Phase 1 and 2 trials relative to Phase 3 suggests a dynamic pipeline with considerable early-stage activity.
141 active
/
1067 total (since 2008)
54
Phase 1 Active
292 total
50
Phase 2 Active
364 total
20
Phase 3 Active
288 total
27
Phase 4 Active
185 total
Top Industry Sponsors
Sorted by active Active Done Failed
Eli Lilly 4 22 7
AstraZeneca 4 20 7
Bristol-Myers Squibb 3 28 2
AbbVie 3 17 2
Novartis 3 12 1
+ 10 more sponsors — see full table below
Featured Phase 3 Trials
NCT04539964 ACTIVE NOT RECRUITING
Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis
SetPoint Medical Corporation n=243
NCT04870203 ACTIVE NOT RECRUITING
Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis
University Hospital, Bordeaux n=160
NCT06915701 RECRUITING
"Effect of Vitamin E (α-Tocopherol) on Clinical Activity and Inflammation in Rheumatoid Arthritis"
University of Guadalajara n=46
NCT06276998 ACTIVE NOT RECRUITING
A Study of LNK01001 Capsule in Subjects With Active Rheumatoid Arthritis (COURAGE-RA)
Lynk Pharmaceuticals Co., Ltd n=430
NCT05814627 ACTIVE NOT RECRUITING
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
AbbVie n=487
+ 283 more Phase 3 trials — see full database below
Rheumatoid Arthritis — Trials Started by Year (last 10 years)
2016 71
2017 44
2018 35
2019 36
2020 25
2021 36
2022 33
2023 39
2024 28
2025 52
2026 30
TheraRadar.com
Full Trial Database
Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.
Top Sponsors (all-time)
Eli Lilly 33
AstraZeneca 31
Bristol-Myers Squibb 33
AbbVie 22
Novartis 16
Guangdong Hengrui Pharmaceutical Co., Ltd 3
Changchun GeneScience Pharmaceutical Co., Ltd. 3
Gilead 12
Merck 8
Hangzhou Highlightll Pharmaceutical Co., Ltd 3
Active Trials by Phase
Phase 1 54
Phase 2 50
Phase 3 20
Phase 4 27
Enrollment Size Distribution
1-50 332
51-200 373
201-500 226
501-1k 73
1k+ 34
All Industry Sponsors
Sorted by active Active Done Failed
Eli Lilly 4 22 7
AstraZeneca 4 20 7
Bristol-Myers Squibb 3 28 2
AbbVie 3 17 2
Novartis 3 12 1
Guangdong Hengrui Pharmaceutical Co., Ltd 3 0 0
Changchun GeneScience Pharmaceutical Co., Ltd. 3 0 0
Gilead 2 8 2
Merck 2 3 3
Hangzhou Highlightll Pharmaceutical Co., Ltd 2 1 0
Kali Therapeutics, Inc. 2 0 0
Citryll BV 2 0 0
Roche 1 72 11
Amgen 1 19 6
Sanofi 1 18 2
NCT04539964 ACTIVE NOT RECRUITING
Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis
SetPoint Medical Corporation n=243
NCT04870203 ACTIVE NOT RECRUITING
Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis
University Hospital, Bordeaux n=160
NCT06915701 RECRUITING
"Effect of Vitamin E (α-Tocopherol) on Clinical Activity and Inflammation in Rheumatoid Arthritis"
University of Guadalajara n=46
NCT06276998 ACTIVE NOT RECRUITING
A Study of LNK01001 Capsule in Subjects With Active Rheumatoid Arthritis (COURAGE-RA)
Lynk Pharmaceuticals Co., Ltd n=430
NCT05814627 ACTIVE NOT RECRUITING
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
AbbVie n=487
NCT05428488 RECRUITING
Efficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis
University Hospital, Montpellier n=220
NCT06726096 ENROLLING BY INVITATION
Phase III Trial of VDJ001 In Patients With Moderate-to-severe Active Rheumatoid Arthritis
Beijing VDJBio Co., LTD. n=615
NCT02629159 ACTIVE NOT RECRUITING
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
AbbVie n=1,629
NCT07008846 ACTIVE NOT RECRUITING
Efficacy of Tofacitinib, Methotrexate Combination Therapy Versus Upadacitinib, Methotrexate Combination Therapy in Moderate to Severe Rheumatoid Arthritis
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh n=96
NCT05756179 RECRUITING
Effect of Diosmin and Hesperidin in Treatment of Patients With Rheumatoid Arthritis
Alexandria University n=80
NCT06887127 RECRUITING
A Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis
Hangzhou Highlightll Pharmaceutical Co., Ltd n=350
NCT06596772 RECRUITING
A Study to Compare Efficacy, Pharmacokinetics, Safety and Immunogenicity of MB04 [proposed Etanercept Biosimilar] to Enbrel® [EU-sourced] in Rheumatoid Arthritis
mAbxience Research S.L. n=458
NCT05092984 RECRUITING
Evaluation of Spironolactone Efficacy in Patient with Rheumatoid Arthritis (RA)
University Hospital, Strasbourg, France n=154
NCT04909801 ACTIVE NOT RECRUITING
A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Bristol-Myers Squibb n=338
NCT06456489 RECRUITING
Pulse Steroid Injection in Refractory Rheumatoid Arthritis
Sohag University n=268
NCT05800327 ACTIVE NOT RECRUITING
A Two-Stage Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Various Doses of Levilimab When Administered Intravenously and Subcutaneously to Healthy Subjects and Subjects With Active Rheumatoid Arthritis
Biocad n=261
NCT03770923 RECRUITING
Effect of Some Drugs on Rheumatoid Arithritis Activity
Sherief Abd-Elsalam n=75
NCT06020144 ACTIVE NOT RECRUITING
A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs
Hangzhou Highlightll Pharmaceutical Co., Ltd n=459
NCT06738719 COMPLETED
A Phase 3 Study to Evaluate Efficacy & Safety of Subcutaneous CT-P13 in Patients With Moderate to Severe Active Rheumatoid Arthritis
Celltrion n=192
NCT05671497 COMPLETED
The Effect of Cilostazol on Rheumatoid Arthritis Patients
Ain Shams University n=70
NCT05379322 WITHDRAWN
The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Patients
Abu Dhabi Stem Cells Center
NCT03025308 COMPLETED
Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis
Alfasigma S.p.A. n=2,731
NCT04077567 COMPLETED
An Extension Study of TS-152 in Subjects With Rheumatoid Arthritis
Taisho Pharmaceutical Co., Ltd. n=401
NCT05246280 TERMINATED
Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA
Navidea Biopharmaceuticals n=169
NCT00650078 COMPLETED
Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra®) Therapy in Patients With Active Rheumatoid Arthritis
Amgen n=350
NCT00984815 COMPLETED
Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment
Amgen n=86
NCT01451203 COMPLETED
Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis
Astellas Pharma Inc n=319
NCT02308163 COMPLETED
A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs
Astellas Pharma Inc n=509
NCT01638013 COMPLETED
A Study to Continue ASP015K Treatment to Rheumatoid Arthritis Patients Who Completed Phase IIb Study or Phase III Study of ASP015K
Astellas Pharma Inc n=843
NCT02305849 COMPLETED
A Study to Evaluate Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to Methotrexate (MTX) Treatment
Astellas Pharma Inc n=519
NCT03660059 COMPLETED
A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)
Astellas Pharma China, Inc. n=385
NCT05489224 COMPLETED
A Study to Compare Efficacy and Safety of CT-P47 and RoActemra in Patients With Rheumatoid Arthritis
Celltrion n=471
NCT05842213 COMPLETED
Comparative, Multicenter Study in Subjects with Rheumatoid Arthritis, ALVOFLEX
Alvotech Swiss AG n=502
NCT03016013 COMPLETED
A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects with Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.
RemeGen Co., Ltd. n=479
NCT04170504 COMPLETED
Efficacy of Chinese Herbal Medicine Qing Re Huo Xue in Patients With Rheumatoid Arthritis
Guang'anmen Hospital of China Academy of Chinese Medical Sciences n=204
NCT06594822 COMPLETED
Effectiveness of Probiotics in Patients of Mild to Moderate Rheumatoid Arthritis
King Edward Medical University n=88
NCT03086343 COMPLETED
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs
AbbVie n=657
NCT06475508 COMPLETED
Comparison of Complarate® (Tocilizumab Biosimilar) and Actemra® in Patients With Rheumatoid Arthritis
AO GENERIUM n=465
NCT01208181 COMPLETED
A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)
Organon and Co n=1,404
NCT00847613 COMPLETED
A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate
Pfizer n=800
NCT03980483 COMPLETED
Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
GlaxoSmithKline n=1,537
NCT04230213 COMPLETED
A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis
Pfizer n=455
NCT04333147 TERMINATED
Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA)
GlaxoSmithKline n=2,916
NCT05545020 COMPLETED
Trivalent Chromium Treatment for Rheumatoid Arthritis
Alexandria University n=60
NCT02706951 COMPLETED
A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)
AbbVie n=648
NCT01664598 COMPLETED
An Extension Study of WA19926 of the Long-Term Safety of Tocilizumab (RoActemra/Actemra) in Patients With Early Moderate to Severe Rheumatoid Arthritis
Hoffmann-La Roche n=49
NCT03970837 TERMINATED
Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)
GlaxoSmithKline n=1,764
NCT03155347 COMPLETED
An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy
Hoffmann-La Roche n=340
NCT04333771 COMPLETED
A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Rheumatoid Arthritis
Jiangsu HengRui Medicine Co., Ltd. n=566
NCT04268771 COMPLETED
A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products
Dr. Reddy's Laboratories Limited n=140
NCT03120949 COMPLETED
Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
R-Pharm International, LLC n=2,106
NCT02760368 COMPLETED
Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease
R-Pharm International, LLC n=428
NCT02760433 COMPLETED
Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease
R-Pharm International, LLC n=368
NCT02760407 COMPLETED
Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease
R-Pharm International, LLC n=1,648
NCT06048224 COMPLETED
Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis
Zhejiang Hisun Pharmaceutical Co. Ltd. n=669
NCT04680962 WITHDRAWN
MabionCD20® Compared to MabThera® and Rituxan® in Patients With Rheumatoid Arthritis
Mabion SA
NCT04134728 COMPLETED
Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors
GlaxoSmithKline n=550
NCT02706873 COMPLETED
A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate
AbbVie n=1,002
NCT04512001 COMPLETED
MSB11456 in Participants With Moderately to Severely Active Rheumatoid Arthritis
Fresenius Kabi SwissBioSim GmbH n=604
NCT02717403 COMPLETED
Effects of Social Networking on Chronic Disease Management in Arthritis
M.D. Anderson Cancer Center n=210
NCT02720523 COMPLETED
A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs
AbbVie n=197
NCT05480878 COMPLETED
Role of Nitazoxanide and Escitalopram in Patients With Rheumatoid Arthritis
Tanta University n=90
NCT02675426 COMPLETED
A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone
AbbVie n=661
NCT04806113 COMPLETED
COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases
McGill University Health Centre/Research Institute of the McGill University Health Centre n=220
NCT02706847 COMPLETED
A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs
AbbVie n=499
NCT02990806 COMPLETED
A Phase 3 Study of NI-071 in Participants With Rheumatoid Arthritis (RADIANCE)
Nichi-Iko Pharmaceutical Co., Ltd. n=683
NCT02373813 COMPLETED
Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission
Amgen n=371
NCT05069714 COMPLETED
One or Two Week Methotrexate Discontinuation on Efficacy of Influenza Vaccination in Rheumatoid Arthritis.
Seoul National University Hospital n=184
NCT01197066 COMPLETED
Open-label, Extension Study of CDP870 in Patients With Rheumatoid Arthritis
Korea Otsuka Pharmaceutical Co., Ltd. n=110
NCT04227366 COMPLETED
Study of the Efficacy and Safety of BCD-089 in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis
Biocad n=154
NCT03522415 COMPLETED
Study of Safety and Efficacy of HLX01+MTX in Patients With Rheumatoid Arthritis
Shanghai Henlius Biotech n=275
NCT01885078 COMPLETED
An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis
Eli Lilly and Company n=2,877
NCT02332590 COMPLETED
Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)
Sanofi n=369
NCT01146652 COMPLETED
Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)
Sanofi n=2,023
NCT00965757 COMPLETED
A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Combination Therapy of T-614 and Methotrexate in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate
Eisai Co., Ltd. n=253
NCT02149121 COMPLETED
PK Similarity Prospective Phase 3 Study in Patients With Rheumatoid Arthritis
Celltrion n=384
NCT02534896 TERMINATED
To Evaluate The Efficacy And Safety Of Sunpharma1505 Compared With Reference1505 In Subjects With Active Rheumatoid Arthritis
Sun Pharmaceutical Industries Limited n=150
NCT03830203 COMPLETED
Comparative Study of BAT1806 to RoActemra® in Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate
Bio-Thera Solutions n=621
NCT04171414 COMPLETED
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
Celltrion n=62
NCT03789292 COMPLETED
A Study to Compare Efficacy and Safety of CT-P17 With Humira in Patients With Active Rheumatoid Arthritis
Celltrion n=648
NCT02955212 COMPLETED
A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)
AbbVie n=338
NCT03707535 COMPLETED
To Compare the Efficacy, Pharmacokinetics and Safety Between CT-P13 and China Approved Remicade When Co-administered With Methotrexate in Patients With Active Rheumatoid Arthritis
Celltrion n=270
NCT02930343 TERMINATED
Comparison of Disease Modifying Antirheumatic Drugs Therapy in Patients With RA Failing Methotrexate Monotherapy
Jawaharlal Institute of Postgraduate Medical Education & Research n=136
NCT02504268 COMPLETED
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
Bristol-Myers Squibb n=994
NCT02889796 COMPLETED
Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
Gilead Sciences n=1,759
NCT02886728 COMPLETED
Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy
Gilead Sciences n=1,252
NCT02873936 COMPLETED
Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment
Gilead Sciences n=449
NCT02304354 COMPLETED
Relationship Between T LYmphocytes Depletion and Clinical Response to RITUXimab in Rheumatoid Arthritis (LYRITUX)
University Hospital, Tours n=70
NCT02746380 COMPLETED
A Study Comparing LBAL to Humira® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy
LG Life Sciences n=383
NCT01394913 WITHDRAWN
Comparison of Two Etanercept Regimens (REUMATOCEPT® Versus ENBREL®) for Treatment of Rheumatoid Arthritis
EMS
NCT03172325 COMPLETED
Study to Demonstrate Non-Inferior Efficacy and Safety of CinnoRA® Versus Humira® for Treatment of Active RA
Cinnagen n=136
NCT02647762 TERMINATED
CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis
Can-Fite BioPharma n=244
NCT00673920 TERMINATED
A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy
Genentech, Inc. n=314
NCT02792699 COMPLETED
Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab
Amgen n=311
NCT01942174 COMPLETED
VACcination In Methotrexate Treated Rheumatoid Arthritis Patients
University Hospital, Montpellier n=276
NCT02468791 COMPLETED
MabionCD20® Compared to MabThera® in Patients With Rheumatoid Arthritis
Mabion SA n=709
NCT02000336 COMPLETED
Comparison of the Effectiveness of Two Different Dosages of Cortisone Compared to Placebo in Rheumatoid Arthritis
Prof. Dr. rer. nat. H.J. Trampisch n=395
NCT03147248 COMPLETED
A Phase I/III Study to Evaluate Efficacy, PK and Safety Between CT-P13 SC and CT-P13 IV in Patients With Active RA
Celltrion n=407
NCT03478111 COMPLETED
CMAB008 With MTX Therapy in Adult Patients With Moderately to Severely Active Rheumatoid Arthritis
Shanghai Biomabs Pharmaceutical Co., Ltd. n=390
NCT01864265 COMPLETED
Prediction of Response to Certolizumab Pegol Treatment by Functional MRI of the Brain
University of Erlangen-Nürnberg Medical School n=156
NCT03052322 COMPLETED
MSB11022 in Moderate to Severe Rheumatoid Arthritis
Fresenius Kabi SwissBioSim GmbH n=288
NCT03357471 COMPLETED
Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease
UCB Biopharma S.P.R.L. n=70
NCT01711359 COMPLETED
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
Eli Lilly and Company n=588
NCT01721057 COMPLETED
A Study in Moderate to Severe Rheumatoid Arthritis Participants
Eli Lilly and Company n=684
NCT01710358 COMPLETED
A Study in Moderate to Severe Rheumatoid Arthritis
Eli Lilly and Company n=1,307
NCT02265705 COMPLETED
A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA)
Eli Lilly and Company n=290
NCT02937701 COMPLETED
Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Infliximab
Amgen n=558
NCT01590966 COMPLETED
Scintigraphic Detection of the Biodistribution of Tumor Necrosis Factor With a Radiolabeled Anti-TNFα in Patients With Active Rheumatoid Arthritis and Active Axial and Peripheral Spondyloarthritis
University Hospital, Ghent n=41
NCT02986139 COMPLETED
Study to Assess the Injection Site Pain Associated With a New Etanercept Formulation in Adults With Rheumatoid Arthritis or Psoriatic Arthritis
Amgen n=111
NCT02566967 COMPLETED
An Evaluation of the Optimal Dose of Tofacitinib Needed to Achieve Low Disease Activity (LDA) or Clinical Remission in Patients With Active Rheumatoid Arthritis (RA) as Measured From a Clinical and Structural Perspective
Norman B. Gaylis, MD n=20
NCT02115750 COMPLETED
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA)
Coherus Oncology, Inc. n=647
NCT02762838 COMPLETED
Comparative Clinical Trial of Efficacy and Safety of BCD-055 and Remicade® in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis
Biocad n=426
NCT01668966 COMPLETED
A Long Term Extension Study of WA19926 (NCT01007435) of Tocilizumab (RoActemra/Actemra) in Participants With Early, Moderate to Severe Rheumatoid Arthritis (RA)
Hoffmann-La Roche n=23
NCT01856309 COMPLETED
Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003
Janssen Research & Development, LLC n=1,820
NCT02405780 COMPLETED
A Study to Compare FKB327 Long-term Safety, Efficacy and Immunogenicity With Humira® in Rheumatoid Arthritis Patients
Fujifilm Kyowa Kirin Biologics Co., Ltd. n=645
NCT02480153 COMPLETED
A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira®) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).
Pfizer n=597
NCT02744755 COMPLETED
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
Sandoz n=353
NCT00960440 COMPLETED
Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors
Pfizer n=399
NCT02046603 COMPLETED
A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent
Hoffmann-La Roche n=162
NCT02640612 COMPLETED
Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis
Boehringer Ingelheim n=430
NCT01941095 COMPLETED
A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis
Hoffmann-La Roche n=100
NCT02001987 COMPLETED
A Study of Tocilizumab (RoActemra) in Tocilizumab-Naive Participants With Rheumatoid Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) and/or Biologic Therapy
Hoffmann-La Roche n=139
NCT02319642 COMPLETED
An Open-label Extension Study of Certolizumab Pegol in Chinese Patients With Rheumatoid Arthritis Who Enrolled in RA0044
UCB Pharma SA n=347
NCT02281552 COMPLETED
A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid Arthritis
Pfizer n=209
NCT02638259 COMPLETED
Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis
Sandoz n=376
NCT01901185 COMPLETED
Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept
Amgen n=77
NCT00753454 COMPLETED
Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)
UCB Pharma n=168
NCT01292265 TERMINATED
A 12 Week Study to Assess Changes in Joint Inflammation Using Ultrasonography in Patients With Rheumatoid Arthritis (RA)
UCB Pharma n=3
NCT00717236 COMPLETED
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
UCB Pharma n=1,648
NCT01519791 COMPLETED
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis
UCB Pharma SA n=880
NCT01521923 COMPLETED
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis
UCB Pharma n=359
NCT02715908 COMPLETED
A Study to Evaluate the Long-term Safety and Efficacy of LBEC0101 in Subjects With Active RA Despite Methotrexate (MTX)
LG Life Sciences n=148
NCT02151851 COMPLETED
A Study of Certolizumab Pegol as Additional Therapy in Chinese Patients With Active Rheumatoid Arthritis
UCB Pharma SA, Belgium n=430
NCT01215942 TERMINATED
An Open Label Study for Participants With Rheumatoid Arthritis
Eli Lilly and Company n=1,086
NCT02222493 COMPLETED
A Study of PF-06438179 (Infliximab-Pfizer) and Infliximab in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (REFLECTIONS B537-02).
Pfizer n=650
NCT02722044 COMPLETED
Usability of an AI for M923 in Subjects With Moderate to Severe RA
Momenta Pharmaceuticals, Inc. n=33
NCT01202773 TERMINATED
A Study in Participants With Rheumatoid Arthritis
Eli Lilly and Company n=456
NCT01198002 TERMINATED
A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methotrexate
Eli Lilly and Company n=1,041
NCT01676701 TERMINATED
Evaluation of Tabalumab Using Auto-Injector or Prefilled Syringe in Participants With Rheumatoid Arthritis (RA)
Eli Lilly and Company n=8
NCT02046616 COMPLETED
A Study of Subcutaneous (SC) Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis (RA) and Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
Hoffmann-La Roche n=133
NCT01039688 COMPLETED
Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX
Pfizer n=956
NCT01606761 COMPLETED
A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)
Janssen Research & Development, LLC n=878
NCT01665430 TERMINATED
A Long-Term Extension Study to WA19926 (NCT01007435) of Tocilizumab in Participants With Early, Moderate to Severe Rheumatoid Arthritis
Hoffmann-La Roche n=38
NCT01682512 TERMINATED
Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis
Boehringer Ingelheim n=294
NCT02373202 COMPLETED
A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)
Sanofi n=91
NCT02293902 COMPLETED
A Study Assessing the Efficacy and Safety of Sarilumab Added to MTX in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis (SARIL-RA-KAKEHASI)
Sanofi n=243
NCT01995201 COMPLETED
A Study of Subcutaneous RoActemra/Actemra (Tocilizumab) as Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis
Hoffmann-La Roche n=401
NCT02744196 COMPLETED
Clinical Trial to Evaluate Efficacy and Safety of Acellbia® (JSC "BIOCAD") With Methotrexate in First Line Biological Therapy of Patients With Active Rheumatoid Arthritis
Biocad n=159
NCT02137226 COMPLETED
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Boehringer Ingelheim n=645
NCT01955733 TERMINATED
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Boehringer Ingelheim n=91
NCT01604343 COMPLETED
A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)
Janssen Research & Development, LLC n=1,670
NCT02514772 COMPLETED
GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera®
Sandoz n=107
NCT01855789 COMPLETED
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX
Hoffmann-La Roche n=718
NCT01213017 COMPLETED
The Effect of Certolizumab Pegol on MRI Synovitis and Bone Edema in Rheumatoid Arthritis Patients
Oklahoma Medical Research Foundation n=20
NCT02260791 COMPLETED
A Study to Compare FKB327 Efficacy and Safety With Humira® in Rheumatoid Arthritis Patients
Fujifilm Kyowa Kirin Biologics Co., Ltd. n=728
NCT03332719 COMPLETED
Efficacy, Safety and Immunogenicity of Enerceptan Compared to Enbrel in Rheumatoid Arthritis
Gema Biotech S.A. n=168
NCT00611455 TERMINATED
Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to MTX Therapy
GlaxoSmithKline n=265
NCT02019472 COMPLETED
A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis
Janssen Research & Development, LLC n=559
NCT02150473 TERMINATED
The Effect of Adalimumab Plus Methotrexate (MTX) Versus Placebo Plus MTX on Cartilage in (RA) Patients
Heinrich-Heine University, Duesseldorf n=21
NCT02553018 COMPLETED
Comparison of Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated by Methotrexate Either by Auto-injector or by Conventional Sub-cutaneous Syringe
Nordic Pharma SAS n=278
NCT01936181 COMPLETED
A Study Comparing SB2 to Remicade® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Samsung Bioepis Co., Ltd. n=584
NCT01063062 COMPLETED
A Study With Tocilizumab [RoActemra/Actemra] Monotherapy or in Combination With Methotrexate in Patients With Rheumatoid Arthritis (PICTURE)
Hoffmann-La Roche n=107
NCT02167139 COMPLETED
A Study Comparing SB5 to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Samsung Bioepis Co., Ltd. n=544
NCT01895309 COMPLETED
A Study Comparing SB4 to Enbrel® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Samsung Bioepis Co., Ltd. n=596
NCT01326962 COMPLETED
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs or Anti-TNF
Hoffmann-La Roche n=28
NCT01709578 COMPLETED
To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)
Sanofi n=546
NCT00951275 COMPLETED
A Study of Tocilizumab + DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis
Hoffmann-La Roche n=105
NCT00848120 COMPLETED
A Study to Assess the Effect of Tocilizumab on Signs and Symptoms in Patients With Rheumatoid Arthritis
Hoffmann-La Roche n=29
NCT00810277 COMPLETED
A Study of Tocilizumab in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic DMARDs
Hoffmann-La Roche n=14
NCT01571219 COMPLETED
An Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 When Co-administered With Methotrexate in Patient With Rheumatoid Arthritis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 3.1
Celltrion n=302
NCT00773461 COMPLETED
A Study of Tocilizumab in Combination With DMARD Therapy in Patients With Active Rheumatoid Arthritis.
Hoffmann-La Roche n=209
NCT02031471 COMPLETED
TOSCARA Study: A Study of Subcutaneous Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis Naïve to RoActemra/Actemra Treatment
Hoffmann-La Roche n=57
NCT01764997 TERMINATED
An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate
Sanofi n=776
NCT01007435 COMPLETED
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Hoffmann-La Roche n=1,162
NCT01941940 COMPLETED
A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants
Hoffmann-La Roche n=227
NCT01061736 COMPLETED
Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients
Sanofi n=1,675
NCT01768572 COMPLETED
To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)
Sanofi n=202
NCT02121210 COMPLETED
To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)
Sanofi n=132
NCT02057250 COMPLETED
To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis
Sanofi n=217
NCT00996606 COMPLETED
A Study of Tocilizumab in Combination With Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Moderate to Severe Active Rheumatoid Arthritis With an Inadequate Response to DMARDs
Hoffmann-La Roche n=58
NCT01987479 COMPLETED
A Study on Safety and Efficacy of Tocilizumab (RoActemra/Actemra) Alone or in Combination With Non-Biologic Antirheumatics in Participants With Rheumatoid Arthritis
Hoffmann-La Roche n=150
NCT02378506 COMPLETED
Study to Assess the Immunogenicity, Safety, and Efficacy of High Capacity Process Etanercept in Rheumatoid Arthritis Subjects
Pfizer n=188
NCT02114931 COMPLETED
Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis
Amgen n=467
NCT00975130 COMPLETED
Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)
Merck Sharp & Dohme LLC n=3,366
NCT01962974 TERMINATED
A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)
Janssen Biotech, Inc. n=7
NCT01377012 COMPLETED
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Novartis Pharmaceuticals n=637
NCT01759030 COMPLETED
Study of Safety and Efficacy of BCD-020 Comparing to MabThera in Patients With Rheumatoid Arthritis
Biocad n=181
NCT01351480 COMPLETED
Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients
Arthritis & Rheumatic Disease Specialties Research n=34
NCT01988012 COMPLETED
A Study of the Efficacy and Safety of Tocilizumab in Adults With Rheumatoid Arthritis.
Hoffmann-La Roche n=100
NCT01694264 TERMINATED
Study of Anti-Viral Prophylaxis for HBsAg(+) or HBcAb(+)/HBsAb(-) Patients Starting Anti-TNFα
Seoul National University Hospital n=43
NCT01655381 COMPLETED
A Long-Term Extension Study of WA19926 on the Safety of Tocilizumab (RoActemra/Actemra) in Participants With Early Moderate to Severe Rheumatoid Arthritis
Hoffmann-La Roche n=15
NCT01970475 COMPLETED
Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
Amgen n=526
NCT01734993 COMPLETED
A Long-Term Extension Study of WA22762 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA).
Hoffmann-La Roche n=11
NCT01772316 COMPLETED
A Long-Term Extension Study of WA22763 and NA25220 of Subcutaneous RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis
Hoffmann-La Roche n=47
NCT01649804 COMPLETED
A Long-Term Safety Extension Study of WA19926 in Participants With Rheumatoid Arthritis
Hoffmann-La Roche n=12
NCT01730456 COMPLETED
A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Early Moderate to Severe Rheumatoid Arthritis Who Completed Study WA19926
Hoffmann-La Roche n=13
NCT02011334 COMPLETED
A Study Assessing the Safety and Efficacy of Subcutaneous RoActemra/Actemra Alone or in Combination With Non-biologic Antirheumatics in Rhuematoid Arthritis Patients in Latin America With Inadequate Response to Non-biologic Antirheumatic Drugs.
Hoffmann-La Roche n=285
NCT01689532 COMPLETED
A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patients With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine
Janssen Pharmaceutical K.K. n=122
NCT01662063 COMPLETED
A Long-Term Extension Study of WA22762 and NA25220 of Subcutaneous (SC) Tocilizumab (TCZ) in Moderate to Severe Rheumatoid Arthritis (RA)
Genentech, Inc. n=218
NCT01951170 COMPLETED
An Open-Label Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis
Hoffmann-La Roche n=52
NCT01770379 TERMINATED
Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents.
Novartis Pharmaceuticals n=242
NCT01034137 COMPLETED
A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis
Hoffmann-La Roche n=317
NCT01194414 COMPLETED
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis
Hoffmann-La Roche n=1,262
NCT01350804 COMPLETED
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)
Novartis Pharmaceuticals n=551
NCT01927263 COMPLETED
A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis
Nichi-Iko Pharmaceutical Co., Ltd. n=242
NCT01244958 COMPLETED
Addition of Rituximab to Leflunomide in Patients With Active Rheumatoid Arthritis
Frank Behrens n=156
NCT00754559 COMPLETED
A Study to Assess Efficacy With Respect to Clinical Improvement in Disease Activity and Safety of Tocilizumab in Patients Wtih Active Rheumatoid Arthritis.
Hoffmann-La Roche n=286
NCT01142726 COMPLETED
Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis
Bristol-Myers Squibb n=511
NCT01214733 COMPLETED
A Study of RoActemra/Actemra (Tocilizumab) Plus DMARDs in Patients With Rheumatoid Arthritis
Hoffmann-La Roche n=30
NCT01830985 COMPLETED
A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subjects With Rheumatoid Arthritis
Vertex Pharmaceuticals Incorporated n=39
NCT02586246 COMPLETED
Long-term Treatment Study of CDP870 Self-injection in Patients With Active Rheumatoid Arthritis Who Are Participating in the Long-term Treatment Studies (Study 275-08-002 or Study 275-08-004) of CDP870
Astellas Pharma Inc n=86
NCT00771251 COMPLETED
A Safety and Efficacy Study of Golimumab (CNTO148) in Patients With Active Rheumatoid Arthritis (RA)
Janssen Pharmaceutical K.K. n=311
NCT01245439 COMPLETED
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis
Hoffmann-La Roche n=65
NCT02164214 COMPLETED
Does Etanercept Influence Tweak Modulation of Inflammation During Inflammatory Rheumatisms (Psoriatic Arthritis and Rheumatoid Arthritis)?
Assistance Publique Hopitaux De Marseille n=60
NCT01332994 COMPLETED
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Hoffmann-La Roche n=519
NCT01140828 COMPLETED
A Study of Rabeprazole for Prevention of Non Steroidal Anti-inflammatory Drug -Associated Gastroduodenal Injury
Chinese University of Hong Kong n=112
NCT01232569 COMPLETED
A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis
Hoffmann-La Roche n=656
NCT01844895 COMPLETED
Methotrexate-Inadequate Response Autoinjector Device Sub Study
Bristol-Myers Squibb n=120
NCT00750880 COMPLETED
An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy.
Hoffmann-La Roche n=1,681
NCT01954381 COMPLETED
Impact of Adalimumab Therapy on Brachial Endothelial Function and Large Artery Stiffness in Patients With Rheumatoid Arthritis
Assistance Publique Hopitaux De Marseille n=60
NCT01587989 COMPLETED
A Study of RoActemra/Actemra (Tocilizumab) With or Without Methotrexate in Patients With Mild to Moderate Rheumatoid Arthritis With an Inadequate Response to Methotrexate
Hoffmann-La Roche n=77
NCT01299961 COMPLETED
Ultrasound Scores as Indication of Response to Subcutaneous Abatacept in Subjects With Rheumatoid Arthritis
University of California, Los Angeles n=25
NCT01395251 COMPLETED
Diagnostic Value of Oral Prednisolone Test for Rheumatoid Arthritis
Rheumazentrum Ruhrgebiet n=130
NCT00754572 COMPLETED
A Study to Assess the Effect of Tocilizumab Plus Methotrexate on Safety and Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis
Hoffmann-La Roche n=418
NCT00661661 COMPLETED
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Pfizer n=487
NCT01004432 COMPLETED
Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
Janssen Biotech, Inc. n=433
NCT00663702 COMPLETED
Phase IIIB Switching From Intravenous to Subcutaneous Study
Bristol-Myers Squibb n=123
NCT01254331 COMPLETED
An Open-label Study With Tocilizumab in Patients With Rheumatoid Arthritis in a Local Environment
Hoffmann-La Roche n=51
NCT01235507 COMPLETED
A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) (ALABASTER)
Hoffmann-La Roche n=71
NCT00850343 COMPLETED
Long-term Treatment Study of Certolizumab Pegol Without Coadministration of Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients
Astellas Pharma Inc n=208
NCT00851318 COMPLETED
Long-term Treatment Study of Certolizumab Pegol (CDP870) as Add-on Medication to Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients
Astellas Pharma Inc n=285
NCT00977106 COMPLETED
TORPEDO Study: A Study on Rapid Effect of Tocilizumab in Patients With Rheumatoid Arthritis With an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) or Anti-TNF
Hoffmann-La Roche n=103
NCT01132118 COMPLETED
Hydroxychloroquine to Improve Insulin Sensitivity in Rheumatoid Arthritis
Brigham and Women's Hospital n=30
NCT00883753 COMPLETED
An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy
Hoffmann-La Roche n=934
NCT00810199 COMPLETED
A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment
Hoffmann-La Roche n=556
NCT01270997 COMPLETED
Randomized Double-blind Parallel Trial to Evaluate Equivalence in Efficacy and Safety of HD203 and Enbrel in RA Patients
Hanwha Chemical n=294
NCT01610791 COMPLETED
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs (REMISSION)
Hoffmann-La Roche n=121
NCT00603525 TERMINATED
Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to TNF-α Antagonist Therapy
GlaxoSmithKline n=169
NCT01353859 COMPLETED
A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDs
Hoffmann-La Roche n=39
NCT01333878 COMPLETED
Impact of Subcutaneous Abatacept in Rheumatoid Arthritis Assessing Inhibition of Structural Damage
Orrin M Troum, M.D. and Medical Associates n=12
NCT01197534 COMPLETED
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.
AstraZeneca n=913
NCT01374971 COMPLETED
Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab Pegol (Cimzia)
Nathan Wei, MD, FACP, FACR: n=12
NCT01197521 COMPLETED
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Not Responding.
AstraZeneca n=923
NCT01197755 COMPLETED
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
AstraZeneca n=323
NCT01242514 TERMINATED
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
AstraZeneca n=1,917
NCT01235598 COMPLETED
Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA)
UCB Pharma n=41
NCT01001832 COMPLETED
Efficacy, Pharmacokinetics, Safety, and Immunogenicity Study of Abatacept Administered Subcutaneously to Treat Rheumatoid Arthritis in Japanese Patients
Bristol-Myers Squibb n=118
NCT00843778 COMPLETED
Follow-up of Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study
UCB Pharma n=131
NCT00973479 COMPLETED
An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy
Centocor, Inc. n=592
NCT01256736 COMPLETED
To Evaluate 1 Year Extension Study of the Efficacy and Safety of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis
JW Pharmaceutical n=89
NCT01185301 COMPLETED
Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA)
AbbVie (prior sponsor, Abbott) n=395
NCT01248780 COMPLETED
Study of Subcutaneous Golimumab in Chinese Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Centocor, Inc. n=264
NCT01781702 COMPLETED
Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. in Rheumatoid Arthritis Patients
Daewon Pharmaceutical Co., Ltd. n=120
NCT01613079 COMPLETED
Efficacy and Safety of Tripterygium Wilfordii in Patients With Rheumatoid Arthritis
Peking Union Medical College Hospital n=201
NCT01793259 COMPLETED
Preference Methotrexate (MTX) Pre-filled Syringe Versus Pre-filled Pen in Rheumatoid Arthritis (RA)
medac GmbH n=120
NCT00767325 COMPLETED
A Rheumatoid Arthritis Study to Assess Early Response to Abatacept+MTX as Defined by Improvement of Synovitis Measures by Power Doppler Ultrasonography
Bristol-Myers Squibb n=104
NCT01873625 COMPLETED
Transplantation of Bone Marrow Derived Mesenchymal Stem Cells in Affected Knee Osteoarthritis by Rheumatoid Arthritis
Royan Institute n=60
NCT01870128 COMPLETED
Comparison of Three Different Treatment Regimes in Early Rheumatoid Arthritis: A Randomized Open-labelled Trial
All India Institute of Medical Sciences n=60
NCT00727987 COMPLETED
A Safety and Efficacy Study of Golimumab (CNTO 148) in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Janssen Pharmaceutical K.K. n=269
NCT01347983 COMPLETED
Extension Study of Tocilizumab Long Term Treatment of Moderate to Severe Rheumatoid Arthritis Patients
Chugai Pharma Taiwan n=72
NCT01044498 COMPLETED
A Study of Tocilizumab in Combination With an Oral Contraceptive in Patients With Rheumatoid Arthritis
Hoffmann-La Roche n=46
NCT01217086 COMPLETED
Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in RA Patients(PLANETRA)
Celltrion n=617
NCT00814307 COMPLETED
A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis
Pfizer n=611
NCT00853385 COMPLETED
A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis
Pfizer n=717
NCT00856544 COMPLETED
A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications
Pfizer n=795
NCT01258712 COMPLETED
Study of Tocilizumab in Combination With Methotrexate for Treatment of Moderate to Severe Rheumatoid Arthritis Patients
Chugai Pharma Taiwan n=86
NCT00891020 COMPLETED
A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)
Hoffmann-La Roche n=886
NCT00993317 COMPLETED
A Study of CDP870 as Add-on Meditation to Methotrexate (MTX) in Patients With Rheumatoid Arthritis
Korea Otsuka Pharmaceutical Co., Ltd. n=127
NCT00690573 COMPLETED
Safety, Efficacy, and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis
Abbott n=25
NCT00791999 COMPLETED
Efficacy Confirmation Trial of CDP870 as add-on Medication to Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)
Otsuka Pharmaceutical Co., Ltd. n=316
NCT00791921 COMPLETED
Efficacy Confirmation Trial of CDP870 Without Coadministration of Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)
Otsuka Pharmaceutical Co., Ltd. n=230
NCT00870467 COMPLETED
A Study of Adalimumab in Japanese Subjects With Rheumatoid Arthritis
Abbott n=334
NCT00674362 COMPLETED
Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study
UCB Pharma n=194
NCT01447264 COMPLETED
Effectiveness of Water Exercises on Isokinetic Muscle Strength
Federal University of São Paulo n=100
NCT00969527 COMPLETED
Efficacy of Oncoxin Plus Viusid in the Treatment of Rheumatoid Arthritis
Catalysis SL n=86
NCT01211834 COMPLETED
Efficacy and Safety of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis
JW Pharmaceutical n=90
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only